US7037917B2ExpiredUtilityA1

HIV replication inhibiting pyrimidines

91
Assignee: JANSSEN PHARMACEUTICA NVPriority: Nov 10, 1998Filed: Aug 5, 2003Granted: May 2, 2006
Est. expiryNov 10, 2018(expired)· nominal 20-yr term from priority
Inventors:Bart De CorteMarc René De JongeJan HeeresChih Yung HoPaul Adriaan Jan JanssenRobert W. KavashLucien Maria Henricus KoymansMichael Joseph KuklaDonald LudoviciKoen Jeanne Alfons Van AkenKOENRAAD JOZEF LODEWIJK MARCEL ANDRIES
A61P 31/18A61P 31/00A61K 31/505A61K 31/5513C07D 239/80C07D 239/47C07D 403/12
91
PatentIndex Score
34
Cited by
50
References
32
Claims

Abstract

This invention concerns the use of compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a 1 =a 2 -a 3 =a 4 - forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R 1 is hydrogen, aryl, formyl, C 1-6 alkylcarbonyl, C 1-6 alkyl, C 1-6 alkyloxycarbonyl, substituted C 1-6 alkyl, or substituted C 1-6 alkyloxyC 1-6 alkylcarbonyl; each R 2 independently is hydroxy, halo, optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C 1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 , —NHC(═O)H, —C(═O)NHNH 2 , —NHC(═O)R 6 , —C(═NH)R 6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl or C 3-7 cycloalkyl; or L is —X—R 3 wherein R 3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR 1 —, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O) 2 —; Q is hydrogen, C 1-6 alkyl, halo, polyhalo-C 1-6 alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C 3-7 cycloalkyl, optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C 1-6 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 , —NHC(═O)H, —C(═O)NHNH 2 , —NHC(═O)R 6 , —C(═NH)R 6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A pyrimidinyl compound 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile, a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof, said compound having the following structure:                  
 
     
     
       2. A pyrimidinyl compound wherein the pyrimidinyl compound is 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile, said compound having the following structure:                  
 
     
     
       3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a pyrimidinyl compound according to any of  claims 1  or  2 . 
     
     
       4. A combination comprising a pyrimidinyl compound according to any of  claims 1  or  2  and an antiretroviral compound, wherein said antiretroviral compound comprises at least one of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a TIBO compound, an α-APA compound, a TAT-inhibitor, a protease inhibitor, an immunomodulating agent, and mixtures thereof. 
     
     
       5. A combination according to  claim 4 , wherein said nucleoside reverse transcriptase inhibitor comprises at least one of zidovudine (3′-azido-3′-deoxythymidine, AZT), didanosine (dideoxy inosine; ddI), zalcitabine (dideoxycytidine, ddC), lamivudine (3′-thia-2′-3′-dideoxycytidine, 3TC), and mixtures thereof. 
     
     
       6. A combination according to  claim 4 , wherein said non-nucleoside reverse transciptase inhibitors comprises at least one of suramine, pentamidine, thymopentin, castanospermine, efavirenz, dextran sulfate, foscarnet-sodium (trisodium phosphono formate), nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2′,3′-e][1,4]diazepin-6-one), tacrine (tetrahydroaminoacridine), and mixtures thereof. 
     
     
       7. A combination according to  claim 4 , wherein said TIBO compound comprises (S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)-thione. 
     
     
       8. A combination according to  claim 4 , wherein said α-APA compound comprises α-[(2-nitro-phenyl)amino]-2,6-dichlorobenzene-acetamide. 
     
     
       9. A combination according to  claim 4 , wherein said protease inhibitor comprises at least one of indinavir, ritanovir, saquinovir, ABT-378, and mixtures thereof. 
     
     
       10. A combination according to  claim 4 , comprising at least one of RO-5-3335, levamisole, and mixtures thereof. 
     
     
       11. A combination according to  claim 5 , further comprising a pharmaceutically acceptable carrier. 
     
     
       12. A combination according to  claim 6 , further comprising a pharmaceutically acceptable carrier. 
     
     
       13. A combination according to  claim 7 , further comprising a pharmaceutically acceptable carrier. 
     
     
       14. A combination according to  claim 8 , further comprising a pharmaceutically acceptable carrier. 
     
     
       15. A combination according to  claim 9 , further comprising a pharmaceutically acceptable carrier. 
     
     
       16. A combination according to  claim 10 , further comprising a pharmaceutically acceptable carrier. 
     
     
       17. A combination according to  claim 4  wherein said pyrimidinyl compound and said antiretroviral compound are combined in a single preparation. 
     
     
       18. A combination according to  claim 17 , further comprising a pharmaceutically acceptable carrier. 
     
     
       19. A process for preparing a compound as claimed in  claim 2 , comprising reacting a compound of formula                  
 
       with NH 3  in the presence of a reaction inert solvent. 
     
     
       20. A process according to  claim 19 , wherein said reacting is performed in the presence of a base. 
     
     
       21. A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject an effective amount of a compound according to  claims 1  or  2 . 
     
     
       22. A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a an effective amount of a combination according to  claim 4 . 
     
     
       23. A pyrimidinyl compound as claimed in  claim 1 , wherein the compound is an addition salt of 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile. 
     
     
       24. A pyriniidinyl compound as claimed in  claim 23 , wherein the compound is the hydrochloride salt of 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile. 
     
     
       25. A pyrimidinyl compound as claimed in  claim 1 , wherein the compound is a quaternary amine of 4-[[4amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile. 
     
     
       26. A pharmaceutical composition as claimed in  claim 3 , wherein the pharmaceutical composition is a tablet. 
     
     
       27. A pharmaceutical composition as claimed in  claim 3 , wherein the effective amount is between 1 to 1000 mg of active ingredient per unit dosage form. 
     
     
       28. A pharmaceutical composition as claimed in  claim 1 , wherein the effective amount is between 5 and 200 mg of active ingredient per unit dosage form. 
     
     
       29. A tablet as claimed in  claim 26 , wherein the effective amount is between 1 to 1000 mg of active ingredient. 
     
     
       30. A tablet as claimed in  claim 29 , wherein the effective amount is between 5 to 200 ing of active ingredient. 
     
     
       31. A method of treating subjects suffering from HIV-1 (Human Immunodeficiency Virus) infection that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors comprising administering to the subject an effective amount of a compound according to any of  claims 1  or  2 . 
     
     
       32. A method of treating subjects suffering from HIV-1 (Human Immunodeficiency Virus) infection that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors comprising administering to the subject an effective amount of a combination comprising a pyrimidinyl compound according to any of  claims 1  or  2  and an antiretroviral compound, wherein said antiretroviral compound comprises at least one of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a TIBO compound, an α-APA compound, a TAT-inhibitor, a protease inhibitor, an immunomodulating agent, and mixtures thereof, and wherein said pyrimidinyl compound and said antiretroviral compound are administered simultaneously, separately or sequentially.

Join the waitlist — get patent alerts

Track US7037917B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.